Selective and noncovalent targeting of RAS mutants for inhibition and degradation

Activating mutants of RAS are commonly found in human cancers, but to date selective targeting of RAS in the clinic has been limited to KRAS(G12C) through covalent inhibitors. Here, we report a monobody, termed 12VC1, that recognizes the active state of both KRAS(G12V) and KRAS(G12C) up to 400-times...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Nat Commun
Päätekijät: Teng, Kai Wen, Tsai, Steven T., Hattori, Takamitsu, Fedele, Carmine, Koide, Akiko, Yang, Chao, Hou, Xuben, Zhang, Yingkai, Neel, Benjamin G., O’Bryan, John P., Koide, Shohei
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Nature Publishing Group UK 2021
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC8113534/
https://ncbi.nlm.nih.gov/pubmed/33976200
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41467-021-22969-5
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia